FumakillalimitedFUMAKILLALIMITED4998東証スタンダード化学FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥3 is left as operating profit. Revenue changed +4.8% from the prior year, operating profit -17.2%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 2.6% | 0.97× | 2.6% | 3.09× | 7.9% |
| 2023 | 1.1% | 1.10× | 1.2% | 3.15× | 3.8% |
| 2024 | 2.0% | 1.13× | 2.3% | 3.25× | 7.5% |
| 2025 | 2.0% | 1.16× | 2.3% | 3.28× | 7.5% |
| 2026 | 1.6% | 1.16× | 1.8% | 3.28× | 5.9% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 52,729 | 61,712 | 67,672 | 73,854 | 77,366 |
| Cost of revenue | 37,065 | 43,971 | 47,661 | 51,302 | 53,434 |
| Gross profit | 15,664 | 17,741 | 20,011 | 22,552 | 23,932 |
| SG&A | 13,481 | 15,847 | 17,607 | 19,905 | 21,741 |
| Operating income | 2,183 | 1,894 | 2,403 | 2,646 | 2,190 |
| Pretax income | 2,665 | 1,715 | 2,766 | 2,644 | 2,285 |
| Income tax | 966 | 759 | 1,079 | 871 | 876 |
| Net income attributable to owners | 1,391 | 668 | 1,377 | 1,462 | 1,206 |
| Operating margin | 4.1% | 3.1% | 3.6% | 3.6% | 2.8% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥6.01B | ¥6.21B | ¥8.17B | ¥9.36B | ¥8.33B |
| Total assets | ¥54.5B | ¥57.4B | ¥62.4B | ¥65B | ¥68.6B |
| Net assets | ¥21.2B | ¥22.9B | ¥25.6B | ¥27.7B | ¥29.3B |
| Share capital | ¥3.7B | ¥3.7B | ¥3.7B | ¥3.7B | ¥3.7B |
| Property, plant and equipment | ¥10.1B | ¥10.2B | ¥10.3B | ¥10.7B | ¥12.3B |
| Intangible assets excluding goodwill | ¥3.69B | ¥3.15B | ¥3.12B | ¥2.97B | ¥2.68B |
| Goodwill | ¥1.42B | ¥1.06B | ¥1B | ¥952M | ¥865M |
| Investment securities | ¥4.94B | ¥4.87B | ¥5.24B | ¥5.18B | ¥6.07B |
| Current assets | ¥34.9B | ¥38.2B | ¥42.4B | ¥44.5B | ¥45.6B |
| Current liabilities | ¥30.5B | ¥31.5B | ¥33.1B | ¥33.2B | ¥33.8B |
| Trade payables | ¥6.49B | ¥6.3B | ¥7.77B | ¥7.37B | ¥7.56B |
| Short-term borrowings | ¥13.5B | ¥15.2B | ¥14.2B | ¥15.5B | ¥16.1B |
| Long-term borrowings | ¥548M | ¥395M | ¥521M | ¥560M | ¥1.54B |
| Total liabilities | ¥33.4B | ¥34.5B | ¥36.8B | ¥37.2B | ¥39.2B |
| Non-controlling interests | ¥1.94B | ¥2.19B | ¥2.42B | ¥2.47B | ¥2.51B |
| Equity attributable to owners of parent | ¥17.6B | ¥17.9B | ¥18.9B | ¥19.9B | ¥20.7B |
| Retained earnings | ¥9.15B | ¥9.44B | ¥10.5B | ¥11.6B | ¥12.4B |
| Treasury stock | -¥7M | -¥7M | -¥8M | -¥9M | -¥10M |
EDINET (FSA Japan)
有価証券報告書－第77期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第76期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第75期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第74期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第73期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第72期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 54 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.